Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 10/20 | 0.58 |
| ▸ | MC5R | P33032 | 10/20 | 0.58 |
| ▸ | MC3R | P41968 | 10/20 | 0.58 |
| ▸ | MC1R | Q01726 | 10/20 | 0.58 |
| ▸ | CTSG | P08311 | 2/20 | 0.54 |
| ▸ | PLAU | P00749 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.53 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.53 |
| ▸ | ITGAV | P06756 | 1/20 | 0.53 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.53 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.53 |
| ▸ | TSLP | Q969D9 | 4/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.51 |
| ▸ | GRB7 | Q14451 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12482122 | 0.95 | MC4R (0.57) | MC4RMC5RMC3RMC1RCTSG | |
| SCHEMBL9908254 | 0.94 | MC4R (0.56) | MC4RMC5RMC3RMC1RCTSG | |
| SCHEMBL10327237 | 0.94 | MC4R (0.57) | MC4RMC5RMC3RMC1RCTSG | |
| SCHEMBL12918029 | 0.93 | MC4R (0.57) | MC4RMC5RMC3RMC1RCTSG | |
| SCHEMBL9909398 | 0.93 | MC4R (0.59) | MC4RMC5RMC3RMC1RCTSG | |
| SCHEMBL13485740 | 0.93 | MC4R (0.58) | MC4RMC5RMC3RMC1RCTSG | |
| SCHEMBL13485887 | 0.93 | MC4R (0.57) | MC4RMC5RMC3RMC1RCTSG | |
| SCHEMBL13486968 | 0.91 | MC4R (0.57) | MC4RMC5RMC3RMC1RCTSG | |
| SCHEMBL14096946 | 0.90 | MC4R (0.59) | MC4RMC5RMC3RMC1RCTSG | |
| SCHEMBL14004103 | 0.89 | MC4R (0.61) | MC4RMC5RMC3RMC1RCTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875701-B2 | A radiopharmaceutical based on a clyclic oligopeptide containing a fluorine isotope and the triplet amino acid sequence of arginine-glycine-aspartic acid (RGD); angiogenesis inhibitors by binding to integrin receptors; imaging using tomography; anticariogenic , -tumor and - arthritic agents; cardiotonic | GE HEALTHCARE AS (NO) | 2011-01-25 | — | — | US | disclosed |
| US-20080095701-A1 | Diagnostic Compounds | SOLBAKKEN MAGNE | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080095701-A1 | Diagnostic Compounds | CA13, SLCO1B3, KLK3 | MC4R 1747/4885MC5R 1385/4885MC3R 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.